Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV
BACKGROUND: Evidence on implementation of three months of weekly isoniazid (H, INH) and rifapentine (P, RPT) (3HP) as a TB preventive therapy (TPT) for at-risk groups in Indian programmatic conditions is limited. METHODS: A prospective demonstration study assessing scale-up, safety, and effectivenes...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-09-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000009/art00005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591366872367104 |
|---|---|
| author | R. Borse B. Randive S. Mattoo P. Malik H. Solanki A. Gupta R.E. Chaisson V. Mave N. Suryavanshi |
| author_facet | R. Borse B. Randive S. Mattoo P. Malik H. Solanki A. Gupta R.E. Chaisson V. Mave N. Suryavanshi |
| author_sort | R. Borse |
| collection | DOAJ |
| description | BACKGROUND: Evidence on implementation of three months of weekly isoniazid (H, INH) and rifapentine (P, RPT) (3HP) as a TB preventive therapy (TPT) for at-risk groups in Indian programmatic conditions is limited. METHODS: A prospective demonstration study assessing scale-up, safety, and effectiveness of 3HP TPT among people living with HIV (PLHIV) in Indian programmatic settings was conducted. RESULTS: Of 656 screened PLHIV, 502 (77%) received 3HP. Of these, 20 (4%) discontinued TPT due to toxicity,17 (3.8%) lost to follow-up, one (0.2%) had breakthrough rifampicin-sensitive TB, and 464 (92%) completed 3 HP TPT. Of 288 (57%) overall adverse events (AEs), 46 (9%) had Grade 2 or above AEs. The median time to AE was 14 days (IQR 7–42). Serious adverse events (SAEs) were reported in 9 (2%) participants; of these, 7 (78%) were not related to 3HP. No TB episodes occurred during the 1-year follow-up period. CONCLUSION: 3HP TPT completion rate of 92%, with few adverse events leading to 3HP discontinuation, providing evidence of the scalability and safety of 3HP TPT among PLHIV in Indian health program settings. |
| format | Article |
| id | doaj-art-4a0e9acd12a8443b84e9fd17549271e3 |
| institution | Kabale University |
| issn | 3005-7590 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-4a0e9acd12a8443b84e9fd17549271e32025-01-22T12:16:08ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-09-011940440910.5588/ijtldopen.23.06095Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIVR. Borse0B. Randive1S. Mattoo2P. Malik3H. Solanki4A. Gupta5R.E. Chaisson6V. Mave7N. Suryavanshi8Byramjee Jeejeebhoy Government Medical College, Pune, India;Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India;Central TB Division, Ministry of Health & Family Welfare, Government of India, New Delhi, India;World Health Organization, Country Office for India, New Delhi, India;World Health Organization, Country Office for India, New Delhi, India;Johns Hopkins University, School of Medicine, Baltimore, MD, USA.Johns Hopkins University, School of Medicine, Baltimore, MD, USA.Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India;Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India;BACKGROUND: Evidence on implementation of three months of weekly isoniazid (H, INH) and rifapentine (P, RPT) (3HP) as a TB preventive therapy (TPT) for at-risk groups in Indian programmatic conditions is limited. METHODS: A prospective demonstration study assessing scale-up, safety, and effectiveness of 3HP TPT among people living with HIV (PLHIV) in Indian programmatic settings was conducted. RESULTS: Of 656 screened PLHIV, 502 (77%) received 3HP. Of these, 20 (4%) discontinued TPT due to toxicity,17 (3.8%) lost to follow-up, one (0.2%) had breakthrough rifampicin-sensitive TB, and 464 (92%) completed 3 HP TPT. Of 288 (57%) overall adverse events (AEs), 46 (9%) had Grade 2 or above AEs. The median time to AE was 14 days (IQR 7–42). Serious adverse events (SAEs) were reported in 9 (2%) participants; of these, 7 (78%) were not related to 3HP. No TB episodes occurred during the 1-year follow-up period. CONCLUSION: 3HP TPT completion rate of 92%, with few adverse events leading to 3HP discontinuation, providing evidence of the scalability and safety of 3HP TPT among PLHIV in Indian health program settings.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000009/art000053hptb preventive therapytb prevention in plhiv |
| spellingShingle | R. Borse B. Randive S. Mattoo P. Malik H. Solanki A. Gupta R.E. Chaisson V. Mave N. Suryavanshi Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV IJTLD Open 3hp tb preventive therapy tb prevention in plhiv |
| title | Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV |
| title_full | Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV |
| title_fullStr | Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV |
| title_full_unstemmed | Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV |
| title_short | Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV |
| title_sort | three months of weekly rifapentine plus isoniazid for tb prevention among people with hiv |
| topic | 3hp tb preventive therapy tb prevention in plhiv |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000009/art00005 |
| work_keys_str_mv | AT rborse threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT brandive threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT smattoo threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT pmalik threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT hsolanki threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT agupta threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT rechaisson threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT vmave threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv AT nsuryavanshi threemonthsofweeklyrifapentineplusisoniazidfortbpreventionamongpeoplewithhiv |